KIM-ANH DO to Myelodysplastic Syndromes
This is a "connection" page, showing publications KIM-ANH DO has written about Myelodysplastic Syndromes.
Connection Strength
0.812
-
Investigating protein patterns in human leukemia cell line experiments: A Bayesian approach for extremely small sample sizes. Stat Methods Med Res. 2020 04; 29(4):1181-1196.
Score: 0.256
-
Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Exp Hematol. 2022 11; 115:44-53.
Score: 0.080
-
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma. 2022 12; 63(13):3154-3164.
Score: 0.080
-
Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS. NEJM Evid. 2022 Oct; 1(10):EVIDoa2200034.
Score: 0.080
-
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J. 2021 03 06; 11(3):52.
Score: 0.072
-
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020 06; 95(6):612-622.
Score: 0.068
-
LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. Leuk Lymphoma. 2020 06; 61(6):1493-1499.
Score: 0.067
-
Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. Leukemia. 2020 03; 34(3):872-881.
Score: 0.066
-
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy. Leukemia. 2007 Mar; 21(3):480-8.
Score: 0.027
-
KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. Blood Adv. 2018 10 09; 2(19):2491-2504.
Score: 0.015